<p>Oramed Pharmaceuticals Inc.（納斯達克代碼：ORMP - 獲取免費報告）在一月份的空頭頭寸顯著增加。截至 1 月 30 日，空頭頭寸總計 644,912 股，比 1 月 15 日的 408,588 股增加了 57.8%。目前，公司 2.0% 的股票被做空。根據平均每日成交量 246,539 股，空頭頭寸比率目前為 2.6 天。</p>
<p>獲取 <strong>Oramed Pharmaceuticals</strong> 的提醒：</p>
<h2>機構資金流入和流出</h2>
<p>幾家機構投資者最近調整了他們在 ORMP 的持股。HRT Financial LP 在第四季度收購了 Oramed Pharmaceuticals 的新股份，價值約為 131,000 美元。Jane Street Group LLC 在第一季度將其在 Oramed Pharmaceuticals 的持股增加了 35.3%。Jane Street Group LLC 目前擁有 67,173 股該生物技術公司的股票，價值 144,000 美元，此前在上個季度又購買了 17,510 股。美國銀行（Bank of America Corp DE）在第三季度將其在 Oramed Pharmaceuticals 的持倉增加了 4.4%。美國銀行目前擁有 149,667 股該生物技術公司的股票，價值 395,000 美元，此前在此期間又購買了 6,261 股。Marshall Wace LLP 在第四季度收購了 Oramed Pharmaceuticals 的股份，價值 738,000 美元。最後，BML Capital Management LLC 在第二季度將其在 Oramed Pharmaceuticals 的持股增加了 2.1%。BML Capital Management LLC 目前擁有 3,083,253 股該生物技術公司的股票，價值 6,937,000 美元，此前在上個季度又購買了 62,505 股。當前 12.73% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師評級變動</h2>
<p>多家券商最近對 ORMP 發佈了報告。Weiss Ratings 在 12 月 29 日的研究報告中重新發布了對 Oramed Pharmaceuticals 股票的 “持有（c）” 評級。Wall Street Zen 在 11 月 1 日的研究報告中將 Oramed Pharmaceuticals 的股票評級提升至 “持有”。根據 MarketBeat.com 的數據，一名股票研究分析師對該股票給予了持有評級，Oramed Pharmaceuticals 目前的共識評級為 “持有”。</p>
<p><strong>獲取我們最新的 Oramed Pharmaceuticals 股票分析</strong></p>
<h2>Oramed Pharmaceuticals 股票上漲 2.5%</h2>
<p>ORMP 股票在週五開盤價為 3.25 美元。該公司的市值為 1.2935 億美元，市盈率為 2.58，貝塔值為 1.34。Oramed Pharmaceuticals 的 12 個月低點為 1.82 美元，12 個月高點為 3.71 美元。該公司的 50 日移動平均價格為 3.22 美元，200 日移動平均價格為 2.65 美元。</p>
<h2>Oramed Pharmaceuticals 分紅公告</h2>
<p>該公司最近宣佈了一項分紅，並於 1 月 26 日（星期一）支付。1 月 16 日（星期五）登記在冊的股東獲得每股 0.25 美元的分紅。該分紅的除息日期為 1 月 16 日（星期五）。Oramed Pharmaceuticals 的分紅支付比率為 19.84%。</p>
<h2>關於 Oramed Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Oramed Pharmaceuticals Inc 是一家臨牀階段的生物技術公司，專注於開發專有的口服藥物遞送系統，最初重點關注糖尿病管理。公司總部位於以色列耶路撒冷，利用其專利的蛋白質包封技術——“口服遞送平台”，將注射療法轉變為患者友好的口服制劑。Oramed 的平台旨在保護敏感的蛋白質和肽免受胃腸道降解，從而實現成功的吸收和系統性遞送。</p>
<p>該公司的主要候選藥物 ORMD-0801 是一種用於 2 型糖尿病患者的口服胰島素膠囊，目前正在進行第三階段臨牀試驗。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Oramed Pharmaceuticals</li>
<li>警報：在 2026 年 1 月之前拋售這五隻股票！</li>
<li>認為你錯過了白銀？你錯了。這是原因。</li>
<li>特朗普的人工智能秘密：比 Nvidia 快 100 倍</li>
<li>你的銀行賬户不再安全</li>
<li>下一個商品危機（比石油還大？）</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Oramed Pharmaceuticals 嗎？</h2>
<p>在你考慮 Oramed Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Oramed Pharmaceuticals 並不在名單上。</p>
<p>雖然 Oramed Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Oramed制藥

<p>Oramed Pharmaceuticals Inc.（納斯達克代碼：ORMP）在 1 月份的空頭頭寸增加了 57.8%，截至 1 月 30 日，總計 644,912 股。這大約佔公司股票的 2.0%，根據平均每日交易量 246,539 股，空頭頭寸比率為 2.6 天。機構投資者持有 12.73% 的股份，公司最近宣佈每股派息 0.25 美元。ORMP 股票開盤價為 3.25 美元，市值為 1.2935 億美元，市盈率為 2.58</p>

<p>Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a significant increase in short interest in January. As of January 30th, there was short interest totaling 644,912 shares, an increase of 57.8% from the January 15th total of 408,588 shares. Currently, 2.0% of the company's stock are short sold. Based on an average daily volume of 246,539 shares, the short-interest ratio is presently 2.6 days. Based on an average daily volume of 246,539 shares, the short-interest ratio is presently 2.6 days. Currently, 2.0% of the company's stock are short sold.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals Inc.（納斯達克代碼：ORMP - 獲取免費報告）在一月份的空頭頭寸顯著增加。截至 1 月 30 日，空頭頭寸總計 644,912 股，比 1 月 15 日的 408,588 股增加了 57.8%。目前，公司 2.0% 的股票被做空。根據平均每日成交量 246,539 股，空頭頭寸比率目前為 2.6 天。</p>
</div><p>Get <strong>Oramed Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Oramed Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several institutional investors have recently modified their holdings of ORMP. HRT Financial LP acquired a new stake in Oramed Pharmaceuticals during the fourth quarter worth approximately $131,000. Jane Street Group LLC lifted its holdings in Oramed Pharmaceuticals by 35.3% during the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock worth $144,000 after purchasing an additional 17,510 shares during the last quarter. Bank of America Corp DE increased its position in Oramed Pharmaceuticals by 4.4% during the 3rd quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company's stock worth $395,000 after buying an additional 6,261 shares during the period. Marshall Wace LLP acquired a new stake in shares of Oramed Pharmaceuticals during the fourth quarter worth $738,000. Finally, BML Capital Management LLC lifted its holdings in shares of Oramed Pharmaceuticals by 2.1% during the second quarter. BML Capital Management LLC now owns 3,083,253 shares of the biotechnology company's stock worth $6,937,000 after buying an additional 62,505 shares in the last quarter. 12.73% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家機構投資者最近調整了他們在 ORMP 的持股。HRT Financial LP 在第四季度收購了 Oramed Pharmaceuticals 的新股份，價值約為 131,000 美元。Jane Street Group LLC 在第一季度將其在 Oramed Pharmaceuticals 的持股增加了 35.3%。Jane Street Group LLC 目前擁有 67,173 股該生物技術公司的股票，價值 144,000 美元，此前在上個季度又購買了 17,510 股。美國銀行（Bank of America Corp DE）在第三季度將其在 Oramed Pharmaceuticals 的持倉增加了 4.4%。美國銀行目前擁有 149,667 股該生物技術公司的股票，價值 395,000 美元，此前在此期間又購買了 6,261 股。Marshall Wace LLP 在第四季度收購了 Oramed Pharmaceuticals 的股份，價值 738,000 美元。最後，BML Capital Management LLC 在第二季度將其在 Oramed Pharmaceuticals 的持股增加了 2.1%。BML Capital Management LLC 目前擁有 3,083,253 股該生物技術公司的股票，價值 6,937,000 美元，此前在上個季度又購買了 62,505 股。當前 12.73% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of brokerages recently issued reports on ORMP. Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Oramed Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen raised shares of Oramed Pharmaceuticals to a &#34;hold&#34; rating in a research report on Saturday, November 1st. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, Oramed Pharmaceuticals presently has a consensus rating of &#34;Hold&#34;.</p>
<div class="lb-trans"><p>多家券商最近對 ORMP 發佈了報告。Weiss Ratings 在 12 月 29 日的研究報告中重新發布了對 Oramed Pharmaceuticals 股票的 “持有（c）” 評級。Wall Street Zen 在 11 月 1 日的研究報告中將 Oramed Pharmaceuticals 的股票評級提升至 “持有”。根據 MarketBeat.com 的數據，一名股票研究分析師對該股票給予了持有評級，Oramed Pharmaceuticals 目前的共識評級為 “持有”。</p>
</div><p><strong>Get Our Latest Stock Analysis on Oramed Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 Oramed Pharmaceuticals 股票分析</strong></p>
</div><h2>Oramed Pharmaceuticals Stock Up 2.5%</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals 股票上漲 2.5%</h2>
</div><p>ORMP stock opened at $3.25 on Friday. The company has a market cap of $129.35 million, a price-to-earnings ratio of 2.58 and a beta of 1.34. Oramed Pharmaceuticals has a twelve month low of $1.82 and a twelve month high of $3.71. The business has a 50 day moving average price of $3.22 and a two-hundred day moving average price of $2.65.</p>
<div class="lb-trans"><p>ORMP 股票在週五開盤價為 3.25 美元。該公司的市值為 1.2935 億美元，市盈率為 2.58，貝塔值為 1.34。Oramed Pharmaceuticals 的 12 個月低點為 1.82 美元，12 個月高點為 3.71 美元。該公司的 50 日移動平均價格為 3.22 美元，200 日移動平均價格為 2.65 美元。</p>
</div><h2>Oramed Pharmaceuticals Dividend Announcement</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals 分紅公告</h2>
</div><p>The company also recently declared a dividend, which was paid on Monday, January 26th. Shareholders of record on Friday, January 16th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, January 16th. Oramed Pharmaceuticals's dividend payout ratio is 19.84%.</p>
<div class="lb-trans"><p>該公司最近宣佈了一項分紅，並於 1 月 26 日（星期一）支付。1 月 16 日（星期五）登記在冊的股東獲得每股 0.25 美元的分紅。該分紅的除息日期為 1 月 16 日（星期五）。Oramed Pharmaceuticals 的分紅支付比率為 19.84%。</p>
</div><h2>About Oramed Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Oramed Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed's platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals Inc 是一家臨牀階段的生物技術公司，專注於開發專有的口服藥物遞送系統，最初重點關注糖尿病管理。公司總部位於以色列耶路撒冷，利用其專利的蛋白質包封技術——“口服遞送平台”，將注射療法轉變為患者友好的口服制劑。Oramed 的平台旨在保護敏感的蛋白質和肽免受胃腸道降解，從而實現成功的吸收和系統性遞送。</p>
</div><p>The company's lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.</p>
<div class="lb-trans"><p>該公司的主要候選藥物 ORMD-0801 是一種用於 2 型糖尿病患者的口服胰島素膠囊，目前正在進行第三階段臨牀試驗。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Oramed Pharmaceuticals</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Think You Missed Silver? You’re Wrong. Here’s Why.</li>
<li>Trump’s AI Secret: 100X Faster Than Nvidia</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>The Next Commodity Crunch (bigger than oil?)</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Oramed Pharmaceuticals</li>
<li>警報：在 2026 年 1 月之前拋售這五隻股票！</li>
<li>認為你錯過了白銀？你錯了。這是原因。</li>
<li>特朗普的人工智能秘密：比 Nvidia 快 100 倍</li>
<li>你的銀行賬户不再安全</li>
<li>下一個商品危機（比石油還大？）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Oramed Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Oramed Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Oramed Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Oramed Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Oramed Pharmaceuticals 並不在名單上。</p>
</div><p>While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Oramed Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Oramed 製藥公司（NASDAQ: ORMP）在 1 月份的空頭頭寸增加了 57.8%